WilmerHale Advises Dyne Therapeutics in $168M Public Offering

WilmerHale Advises Dyne Therapeutics in $168M Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Dyne Therapeutics, Inc., a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, in connection with its follow-on offering of common stock. The gross proceeds to Dyne were approximately $168 million, before deducting underwriting discounts and offering expenses. The offering priced on January 20, 2021 and closed on January 25, 2021.

The WilmerHale team representing Dyne was led by Stuart Falber, and included Scott Lunin, Mike Lopes, Erin Garrity, Lauren Roberts, Ciara Baker, Bruce Manheim and Heidi Treiber.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel